Share This:
Add to Your Calendar:
School of Health Lecture Series
This session highlights the persistent underrepresentation of African populations in genomic research despite Africa’s unparalleled genetic diversity and potential to drive global breakthroughs in precision medicine. Using Yemaachi Biotech, a pan-African cancer genomics company in Ghana, as a case study, it examines how African-led innovation can close gaps in drug discovery, disease prediction, and therapeutic development. ³Û±ð³¾²¹²¹³¦³ó¾±â€™s model, which combines local clinical partnerships, advanced genomic sequencing, and translational R&D, illustrates how African biotech can advance both local health priorities and global pharmaceutical needs. The discussion underscores the importance of scientific sovereignty, equitable data ownership, and African leadership, framing African biotech not as a passive data source but as an active driver of innovation in the future of precision medicine.